70 results on '"Capello, Daniela"'
Search Results
2. UPO Biobank: The Challenge of Integrating Biobanking into the Academic Environment to Support Translational Research.
- Author
-
Bettio, Valentina, Mazzucco, Eleonora, Aleni, Chiara, Cracas, Silvia, Rinaldi, Carmela, Antona, Annamaria, Varalda, Marco, Venetucci, Jacopo, Ferrante, Daniela, Rimedio, Antonio, and Capello, Daniela
- Subjects
TRANSLATIONAL research ,BIOLOGICAL specimens ,INDIVIDUALIZED medicine ,BIOMATERIALS ,LONGITUDINAL method - Abstract
Biobanks are driving motors of precision and personalized medicine by providing high-quality biological material/data through the standardization and harmonization of their collection, preservation, and distribution. UPO Biobank was established in 2020 as an institutional, disease, and population biobank within the University of Piemonte Orientale (UPO) for the promotion and support of high-quality, multidisciplinary studies. UPO Biobank collaborates with UPO researchers, sustaining academic translational research, and supports the Novara Cohort Study, a longitudinal cohort study involving the population in the Novara area that will collect data and biological specimens that will be available for epidemiological, public health, and biological studies on aging. UPO Biobank has been developed by implementing the quality standards for the field and the ethical and legal issues and normative about privacy protection, data collection, and sharing. As a member of the "Biobanking and Biomolecular Resources Research Infrastructure" (BBMRI) network, UPO Biobank aims to expand its activity worldwide and launch cooperation with new national and international partners and researchers. The objective of this manuscript is to report an institutional and operational experience through the description of the technical and procedural solutions and ethical and scientific implications associated with the establishment of this university research biobank. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Extracellular vesicles from human plasma for biomarkers discovery: Impact of anticoagulants and isolation techniques.
- Author
-
Bettio, Valentina, Mazzucco, Eleonora, Antona, Annamaria, Cracas, Silvia, Varalda, Marco, Venetucci, Jacopo, Bruno, Stefania, Chiabotto, Giulia, Venegoni, Chiara, Vasile, Alessandra, Chiocchetti, Annalisa, Quaglia, Marco, Camussi, Giovanni, Cantaluppi, Vincenzo, Panella, Massimiliano, Rolla, Roberta, Manfredi, Marcello, and Capello, Daniela
- Subjects
EXTRACELLULAR vesicles ,PLASMA confinement ,ANTICOAGULANTS ,ULTRACENTRIFUGATION ,FATTY acids ,PROTEIN S - Abstract
Extracellular vesicles (EVs) isolated from plasma are increasingly recognized as promising circulating biomarkers for disease discovery and progression, as well as for therapeutic drug delivery. The scientific community underlined the necessity of standard operative procedures for the isolation and storage of the EVs to ensure robust results. The understanding of the impact of the pre-analytical variables is still limited and some considerations about plasma anticoagulants and isolation methods are necessary. Therefore, we performed a comparison study between EVs isolated by ultracentrifugation and by affinity substrate separation from plasma EDTA and sodium citrate. The EVs were characterized by Nano Tracking Analysis, Western Blot, cytofluorimetric analysis of surface markers, and lipidomic analysis. While anticoagulants did not significantly alter any of the analyzed parameters, the isolation methods influenced EVs size, purity, surface markers expression and lipidomic profile. Compared to ultracentrifugation, affinity substrate separation yielded bigger particles highly enriched in tetraspanins (CD9, CD63, CD81), fatty acids and glycerolipids, with a predominant LDL- and vLDL-like contamination. Herein, we highlighted that the isolation method should be carefully evaluated prior to study design and the need of standardized operative procedures for EVs isolation and application to biomarkers discovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The prevention of falls in patients with Parkinson's disease with in-home monitoring using a wearable system: a pilot study protocol.
- Author
-
Campani, Daiana, De Luca, Enrico, Bassi, Erika, Busca, Erica, Airoldi, Chiara, Barisone, Michela, Canonico, Massimo, Contaldi, Elena, Capello, Daniela, De Marchi, Fabiola, Magistrelli, Luca, Mazzini, Letizia, Panella, Massimiliano, Scotti, Lorenza, Invernizzi, Marco, and Dal Molin, Alberto
- Subjects
PILOT projects ,MEDICAL quality control ,SCIENTIFIC observation ,HOME care services ,FUNCTIONAL status ,WEARABLE technology ,PATIENT monitoring ,PHYSICAL activity ,ACCIDENTAL falls ,PARKINSON'S disease ,TELEMEDICINE ,LONGITUDINAL method ,NEURODEGENERATION ,DISEASE complications - Abstract
Background: Parkinson's disease (PD) is a chronic, progressive neurodegenerative condition that gradually worsens motor function and leads to postural instability and, eventually, falls. Several factors may influence the frequency of future falls, such as slowness, freezing of gait, loss of balance, and mobility problems, cognitive impairments, and the number of previous falls. The TED bracelet is an advanced technological wearable device able to predict falls. Aims: This principal aim is to investigate the feasibility of a full-scale research project that uses the TED bracelet to identify whether individuals with PD are at risk of falling. Methods: This study will involve a pilot prospective observational study design; the subjects will include 26 patients suffering from mild PD and 26 others with no PD and no gait problems. Data will be collected from the TED bracelet and then compared to a paper-based fall diary. The enrolled participants will have a scheduled outpatient evaluation to collect both clinical and instrumental data as well as biological samples. Discussion: This pilot study could then be implemented in a larger form to further evaluate the effectiveness of the TED device. Finally, it will help further develop gait monitoring systems for people with Parkinson's disease and other neurodegenerative diseases that can affect physical function and mobility, such as dementia and Alzheimer's. Conclusions: Preventing falls and their complications could lead to major advancements in the quality of home care for patients with PD, which would significantly impact the quality of life of both these patients and their caregivers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Public Attitude towards Biobanking: An Italian University Survey.
- Author
-
Aleni, Chiara, Rinaldi, Carmela, Bettio, Valentina, Mazzucco, Eleonora, Antona, Annamaria, Meini, Cristina, Loria, Emiliano, Bonvicini, Paolo, Cracas, Silvia Vittoria, Caristia, Silvia, Rimedio, Antonio, Faggiano, Fabrizio, Ferrante, Daniela, and Capello, Daniela
- Published
- 2022
- Full Text
- View/download PDF
6. Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors.
- Author
-
Velnati, Suresh, Massarotti, Alberto, Antona, Annamaria, Talmon, Maria, Fresu, Luigia Grazia, Galetto, Alessandra Silvia, Capello, Daniela, Bertoni, Alessandra, Mercalli, Valentina, Graziani, Andrea, Tron, Gian Cesare, and Baldanzi, Gianluca
- Subjects
STRUCTURE-activity relationships ,SEROTONIN antagonists ,SEROTONIN receptors ,CELL migration ,MOLECULAR models - Abstract
A series of analogues of Amb639752, a novel diacylglycerol kinase (DGK) inhibitor recently discovered by us via virtual screening, have been tested. The compounds were evaluated as DGK inhibitors on α, θ, and ζ isoforms, and as antagonists on serotonin receptors. From these assays emerged two novel compounds, namely 11 and 20, which with an IC
50 respectively of 1.6 and 1.8 µM are the most potent inhibitors of DGKα discovered to date. Both compounds demonstrated the ability to restore apoptosis in a cellular model of X-linked lymphoproliferative disease as well as the capacity to reduce the migration of cancer cells, suggesting their potential utility in preventing metastasis. Finally, relying on experimental biological data, molecular modelling studies allow us to set a three-point pharmacophore model for DGK inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function.
- Author
-
Varalda, Marco, Antona, Annamaria, Bettio, Valentina, Roy, Konkonika, Vachamaram, Ajay, Yellenki, Vaibhav, Massarotti, Alberto, Baldanzi, Gianluca, and Capello, Daniela
- Subjects
PSYCHIATRIC drugs ,ANTINEOPLASTIC agents ,CELL death ,MITOCHONDRIAL membranes ,CANCER cells ,AMPHIPHILES - Abstract
Background and Purpose: Drug repositioning is a promising strategy for discovering new therapeutic strategies for cancer therapy. We investigated psychotropic drugs for their antitumor activity because of several epidemiological studies reporting lower cancer incidence in individuals receiving long term drug treatment. Experimental Approach: We investigated 27 psychotropic drugs for their cytotoxic activity in colorectal carcinoma, glioblastoma and breast cancer cell lines. Consistent with the cationic amphiphilic structure of the most cytotoxic compounds, we investigated their effect on mitochondrial and lysosomal compartments. Results: Penfluridol, ebastine, pimozide and fluoxetine, fluspirilene and nefazodone showed significant cytotoxicity, in the low micromolar range, in all cell lines tested. In MCF7 cells these drugs caused mitochondrial membrane depolarization, increased the acidic vesicular compartments and induced phospholipidosis. Both penfluridol and spiperone induced AMPK activation and autophagy. Neither caspase nor autophagy inhibitors rescued cells from death induced by ebastine, fluoxetine, fluspirilene and nefazodone. Treatment with 3-methyladenine partially rescued cell death induced by pimozide and spiperone, whereas enhanced the cytotoxic activity of penfluridol. Conversely, inhibition of lysosomal cathepsins significantly reduced cell death induced by ebastin, penfluridol, pimozide, spiperone and mildly in fluoxetine treated cells. Lastly, Spiperone cytotoxicity was restricted to colorectal cancer and breast cancer and caused apoptotic cell death in MCF7 cells. Conclusions: The cytotoxicity of psychotropic drugs with cationic amphiphilic structures relied on simultaneous mitochondrial and lysosomal disruption and induction of cell death that not necessarily requires apoptosis. Since dual targeting of lysosomes and mitochondria constitutes a new promising therapeutic approach for cancer, particularly those in which the apoptotic machinery is defective, these data further support their clinical development for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression.
- Author
-
Poli, Alessandro, Fiume, Roberta, Baldanzi, Gianluca, Capello, Daniela, Ratti, Stefano, Gesi, Marco, Manzoli, Lucia, Graziani, Andrea, Suh, Pann‐Ghill, Cocco, Lucio, and Follo, Matilde Y.
- Subjects
DIGLYCERIDES ,CELL cycle ,PHOSPHATIDYLINOSITOLS ,CELLULAR signal transduction ,CELL proliferation - Abstract
Phosphatidylinositol (PI) signaling is an essential regulator of cell motility and proliferation. A portion of PI metabolism and signaling takes place in the nuclear compartment of eukaryotic cells, where an array of kinases and phosphatases localize and modulate PI. Among these, Diacylglycerol Kinases (DGKs) are a class of phosphotransferases that phosphorylate diacylglycerol and induce the synthesis of phosphatidic acid. Nuclear DGKalpha modulates cell cycle progression, and its activity or expression can lead to changes in the phosphorylated status of the Retinoblastoma protein, thus, impairing G1/S transition and, subsequently, inducing cell cycle arrest, which is often uncoupled with apoptosis or autophagy induction. Here we report for the first time not only that the DGKalpha isoform is highly expressed in the nuclei of human erythroleukemia cell line K562, but also that its nuclear activity drives K562 cells through the G1/S transition during cell cycle progression. J. Cell. Physiol. 232: 2550-2557, 2017. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas.
- Author
-
Rinaldi, Andrea, Capello, Daniela, Zucca, Emanuele, Gaidano, Gianluca, and Bertoni, Francesco
- Published
- 2013
- Full Text
- View/download PDF
10. The Diacylglycerol Kinase α/Atypical PKC/β1 Integrin Pathway in SDF-1α Mammary Carcinoma Invasiveness.
- Author
-
Rainero, Elena, Cianflone, Cristina, Porporato, Paolo Ettore, Chianale, Federica, Malacarne, Valeria, Bettio, Valentina, Ruffo, Elisa, Ferrara, Michele, Benecchia, Fabio, Capello, Daniela, Paster, Wolfgang, Locatelli, Irene, Bertoni, Alessandra, Filigheddu, Nicoletta, Sinigaglia, Fabiola, Norman, Jim C., Baldanzi, Gianluca, and Graziani, Andrea
- Subjects
DIGLYCERIDES ,PROTEIN kinases ,INTEGRINS ,CANCER invasiveness ,PHOSPHATIDIC acids ,CELLULAR signal transduction ,EPITHELIAL cells ,CANCER cell migration - Abstract
Diacylglycerol kinase α (DGKα), by phosphorylating diacylglycerol into phosphatidic acid, provides a key signal driving cell migration and matrix invasion. We previously demonstrated that in epithelial cells activation of DGKα activity promotes cytoskeletal remodeling and matrix invasion by recruiting atypical PKC at ruffling sites and by promoting RCP-mediated recycling of α5β1 integrin to the tip of pseudopods. In here we investigate the signaling pathway by which DGKα mediates SDF-1α-induced matrix invasion of MDA-MB-231 invasive breast carcinoma cells. Indeed we showed that, following SDF-1α stimulation, DGKα is activated and localized at cell protrusion, thus promoting their elongation and mediating SDF-1α induced MMP-9 metalloproteinase secretion and matrix invasion. Phosphatidic acid generated by DGKα promotes localization at cell protrusions of atypical PKCs which play an essential role downstream of DGKα by promoting Rac-mediated protrusion elongation and localized recruitment of β1 integrin and MMP-9. We finally demonstrate that activation of DGKα, atypical PKCs signaling and β1 integrin are all essential for MDA-MB-231 invasiveness. These data indicates the existence of a SDF-1α induced DGKα - atypical PKC - β1 integrin signaling pathway, which is essential for matrix invasion of carcinoma cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
- Author
-
Varettoni, Marzia, Zibellini, Silvia, Capello, Daniela, Arcaini, Luca, Rossi, Davide, Pascutto, Cristiana, Rattotti, Sara, Mangiacavalli, Silvia, Pochintesta, Lara, Gotti, Manuel, Gaidano, Gianluca, and Cazzola, Mario
- Subjects
ETIOLOGY of diseases ,IMMUNOGLOBULIN M ,LYMPHOCYTIC leukemia ,GLOBULINS ,MACROGLOBULINS ,B cells ,DISEASES ,PATIENTS - Abstract
We characterized immunoglobulin heavy chain (IGH) gene rearrangements and searched for clusters of stereotyped B-cell receptors in 123 patients with Waldenström macroglobulinemia (WM; n = 59) or immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MGUS) ( n = 64). A productive monoclonal IGHV-D-J rearrangement was obtained in 99/123 patients (80%). Immunoglobulin heavy chain variable (IGHV) genes were mutated in 94/99 patients (95%) with a median somatic hypermutation rate of 6.7% (2.1-14.5). Compared with the normal B-cell repertoire, patients with WM/IgM-MGUS showed an over-representation of the IGHV3 subgroup (83% vs. 55%, p < 0.0001) and an under-representation of IGHV1 (7% vs. 14%, p = 0.04) and IGHV4 (7% vs. 23%, p = 0.0001) subgroups. At the gene level, in WM/IgM-MGUS there was an over-representation of IGHV3-23 (24% vs. 12%, p = 0.0003), IGHV3-64 (3% vs. < 1%, p = 0.003), IGHV3-7 (12% vs. 4%, p = 0.0001) and IGHV3-74 (9% vs. 2%, p < 0.0001), while IGHV4-39 was never used (0 vs. 5%, p = 0.03). Intra-WM/IgM-MGUS search for HCDR3 similarity showed no association fulfilling criteria for stereotyped receptors. WM/IgM-MGUS sequences were unrelated to known chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL) or mantle cell lymphoma (MCL) subsets. In conclusion, the IGHV gene usage in WM and IgM-MGUS is remarkably biased as compared to the normal B-cell repertoire. WM and IgM-MGUS-specific HCDR3 clusters do not occur with a frequency detectable with currently available databases, not supporting a B-cell receptor-driven pathogenesis in WM and IgM-MGUS. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
- Author
-
Capello, Daniela, Gloghini, Annunziata, Baldanzi, Gianluca, Martini, Maurizio, Deambrogi, Clara, Lucioni, Marco, Piranda, Daniela, Famà, Rosella, Graziani, Andrea, Spina, Michele, Tirelli, Umberto, Paulli, Marco, Larocca, Luigi Maria, Gaidano, Gianluca, Carbone, Antonino, and Sinigaglia, Fabiola
- Abstract
We investigated immunodeficiency-related non-Hodgkin lymphoma for the presence of molecular alterations affecting negative regulators of the Janus family protein tyrosine kinase/signal transducer and activator of transcription pathway. Protein tyrosine phosphatase, non-receptor type 6/Src homology 2-containing tyrosine phosphatase-1 epigenetic silencing was recurrent in primary effusion lymphoma (100%), and diffuse large B-cell lymphoma (63%), with a higher prevalence in the non-germinal centre subtype, and was associated with the activation of the Janus family protein tyrosine kinase/signal transducer and activator of transcription 3 pathway. Suppressor of cytokine signalling ( SOCS)1 and SOCS3 epigenetic silencing were occasionally detected, whereas SOCS1 was frequently mutated in diffuse large B-cell lymphoma and polymorphic post-transplant lymphoproliferative disorders, possibly as a cause of aberrant somatic hypermutation. However, the mutation profile of the coding region of the gene was different from that expected from the aberrant somatic hypermutation process, suggesting that, at least in some cases, SOCS1 mutations may have been selected for their functional activity. Copyright © 2012 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis.
- Author
-
Rossi, Davide, Spina, Valeria, Forconi, Francesco, Capello, Daniela, Fangazio, Marco, Rasi, Silvia, Martini, Maurizio, Gattei, Valter, Ramponi, Antonio, Larocca, Luigi M., Bertoni, Francesco, and Gaidano, Gianluca
- Abstract
Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia to aggressive lymphoma. We explored intraclonal diversification (ID) of immunoglobulin genes in order to ( i) follow the evolutionary history of the RS clone ( ii) compare the role of ID in clonally related RS vs. clonally unrelated cases. Most (10/11, 90.9%) clonally related RS stem from the predominant clone observed at CLL diagnosis. One single RS had a transformation pattern compatible with sequential evolution from a secondary CLL subclone. Once RS transformation had occurred, all secondary CLL subclones disappeared and were substituted by the dominant RS clone with its own descendants. These observations suggest that genetic lesions associated with RS transformation are acquired by a cell belonging to the original CLL clone, rather than being progressively accumulated by later CLL subclones. Accordingly, most (9/11, 81.1%) clonally related RS harbored a genetic lesion disrupting TP53 that was already present, though at subclonal levels, in 5/11 (45.5%) samples of the paired CLL phase. A fraction of clonally related RS switched off ID (4/11, 36.4%) or reduced the levels of ID (5/11, 45.4%) at transformation. Conversely, all clonally unrelated RS harbored ID and were characterized by a significantly higher mutation frequency compared to clonally related RS (median: 1.18 × 10
−3 vs. 0.13 × 10-3 ; p =0.002). These data indicate that ( i) clonally related RS stems from a cell that is already present within the initial CLL clone and ( ii) clonally unrelated and clonally related RS are biologically distinct disorders also in terms of antigen affinity maturation. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
14. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array.
- Author
-
Kwee, Ivo, Rinaldi, Andrea, Rancoita, Paola, Rossi, Davide, Capello, Daniela, Forconi, Francesco, Giuliani, Nicola, Piva, Roberto, Inghirami, Giorgio, Gaidano, Gianluca, Zucca, Emanuele, and Bertoni, Francesco
- Subjects
DNA ,DNA methylation ,LYMPHOMAS ,METHYLATION ,CANCER ,TUMORS - Abstract
Summary Changes in DNA copy number (CN) and DNA methylation represent important aberrations for lymphomas and other cancers. Here, for the first time, we show that the Illumina Infinium Methylation (IIM) assay, although not originally designed for CN profiling, is able to estimate CN changes. We compared the IIM CN profiles to those obtained with a standard technique in a series of diffuse large B-cell lymphomas: the profiles showed a high degree of consensus. The demonstration of CN profiling as an additional function of the IIM assay may impact the choice of platform for methylation profiling of haematological and solid tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma.
- Author
-
Kwee, Ivo, Capello, Daniela, Rinaldi, Andrea, Rancoita, Paola M. V., Bhagat, Govind, Greiner, Tim C., Spina, Michele, Gloghini, Annunziata, Chan, Wing C., Paulli, Marco, Zucca, Emanuele, Tirelli, Umberto, Carbone, Antonino, Gaidano, Gianluca, and Bertoni, Francesco
- Subjects
B cell lymphoma ,HIV antibodies ,UNIVARIATE analysis ,IMMUNOCOMPETENT cells ,IMMUNODEFICIENCY ,PATIENTS - Abstract
The objective of this study was to evaluate the prognostic impact of genomic regions in a series of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphomas (HIV-DLBCLs) and post-transplant DLBCLs (PT-DLBCLs) analyzed by genome-wide DNA profiling. Minimal common regions (MCRs) were estimated on genomic profiles obtained using Affymetrix Human Mapping 250k Nsp I arrays and tested for their impact on clinical outcome by univariate analysis on 36 PT-DLBCLs, 19 HIV-DLBCLs and, as a control group, 149 DLBCLs arising in immunocompetent individuals (IC-DLBCLs). PT-DLBCL and HIV-DLBCL presented a similar outcome. Immunodeficiency-related DLBCL (ID-DLBCL) had a worse overall survival (OS) than IC-DLBCL. Seven MCRs showed a statistical impact on OS in PT-DLBCL and four in HIV-DLBCL. Among these, the presence of gains at 1q or at 18q defined a group of patients with PT-DLBCL with a very poor outcome ( p < 0.0001). The presence of del(3p14.2) or of ++ 2p23.1 identified a group of HIV-DLBCLs with a very poor outcome ( p == 0.0072). It was concluded that genomic aberrations affecting outcome differ between ID-DLBCL and IC-DLBCL and are also dependent on the type of acquired immunodeficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
16. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.
- Author
-
Dal-Bo, Michele, Del Giudice, Ilaria, Bomben, Riccardo, Capello, Daniela, Bertoni, Francesco, Forconi, Francesco, Laurenti, Luca, Rossi, Davide, Zucchetto, Antonella, Pozzato, Gabriele, Marasca, Roberto, Efremov, Dimitar G., Guarini, Anna, Del Poeta, Giovanni, Foà, Robin, Gaidano, Gianluca, and Gattei, Valter
- Subjects
B cells ,CELL receptors ,IMMUNOGLOBULINS ,GENES ,CHRONIC lymphocytic leukemia ,PROGNOSIS - Abstract
The immunoglobulin heavy chain variable gene ( IGHV) mutational status has been recognized as an important predictor of prognosis in chronic lymphocytic leukaemia (CLL) since 1999. More recently, other features of the B-cell receptor, such as stereotypy, have been identified as capable of refining the prognostic potential of IGHV status in the clinical assessment of CLL patients. In this context, different genes belonging to the IGHV3 subgroup, the most frequently used subgroup in CLL, have been shown to denote disease subsets that either display a bad prognosis (i.e. IGHV3-21, IGHV3-23) or are associated with particularly good clinical outcomes, including a highly stable/indolent clinical course, even prone to spontaneous regression (i.e. IGHV3-72, IGHV3-30). The present review focuses on the molecular and biological features of CLL-expressing specific genes belonging to the IGHV3 subgroup that are known to mark disease subsets with completely different clinical courses, and may be possibly related to CLL pathogenesis via antigen and/or superantigen involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.
- Author
-
Capello, Daniela, Gloghini, Annunziata, Martini, Maurizio, Spina, Michele, Tirelli, Umberto, Bertoni, Francesco, Rinaldi, Andrea, Morra, Enrica, Rambaldi, Alessandro, Sinigaglia, Fabiola, Larocca, Luigi Maria, and Carbone, Antonino
- Subjects
GENETIC mutation ,LYMPHOMAS ,HODGKIN'S disease ,IMMUNODEFICIENCY ,POLYMERASE chain reaction - Abstract
The article discusses a study which investigated the involvement of CD79A, EZH2, and CD79B gene mutations in immunodeficiency-related non-Hodgkin lymphomas (ID-NHL). Using polymerase chain reaction amplification and direct sequencing, the study identified only EZH2 mutations in 3/116 ID-NHL primary samples. It notes that among the immunocompetent hosts' aggressive NHL, EZH2 mutations are selectively confined to cases of diffuse large B-cell lymphoma (DLBCL) with a germinal centre (GC) phenotype.
- Published
- 2011
- Full Text
- View/download PDF
18. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma.
- Author
-
Rinaldi, Andrea, Capello, Daniela, Scandurra, Marta, Greiner, Timothy C., Chan, Wing C., Bhagat, Govind, Rossi, Davide, Morra, Enrica, Paulli, Marco, Rambaldi, Alessandro, Rancoita, Paola M. V., Inghirami, Giorgio, Ponzoni, Maurilio, Moreno, Santiago M., Piris, Miguel A., Mian, Michael, Chigrinova, Ekaterina, Zucca, Emanuele, Favera, Riccardo D., and Gaidano, Gianluca
- Subjects
LYMPHOMA treatment ,GENETIC polymorphisms ,CARCINOGENESIS ,TRANSPLANTATION immunology ,HLA histocompatibility antigens ,B cell lymphoma - Abstract
Post-transplant lymphoproliferative disorders (PTLD) are complications of solid organ transplantation associated with severe morbidity and mortality. Diffuse large B-cell lymphoma (DLBCL) represents the most common form of monomorphic PTLD. We studied 44 cases of post-transplant DLBCL (PT-DLBCL) with high-density genome wide single nucleotide polymorphism-based arrays, and compared them with 105 cases of immunocompetent DLBCL (IC-DLBCL) and 28 cases of Human Immunodeficiency Virus-associated DLBCL (HIV-DLBCL). PT-DLBCL showed a genomic profile with specific features, although their genomic complexity was overall similar to that observed in IC- and HIV-DLBCL. Among the loci more frequently deleted in PT-DLBCL there were small interstitial deletions targeting known fragile sites, such as FRA1B, FRA2E and FRA3B. Deletions at 2p16.1 (FRA2E) were the most common lesions in PT-DLBCL, occurring at a frequency that was significantly higher than in IC-DLBCL. Genetic lesions that characterized post-germinal center IC-DLBCL were under-represented in our series of PT-DLBCL. Two other differences between IC-DLBCL and PT-DLBCL were the lack of del(13q14.3) ( MIR15/MIR16) and of copy neutral LOH affecting 6p [major histocompatibility complex (MHC) locus] in the latter group. In conclusion, PT-DLBCL presented unique features when compared with IC-DLBCL. Changes in PT-DLBCL were partially different to those in HIV-DLBCL, suggesting different pathogenetic mechanisms in the two conditions linked to immunodeficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort.
- Author
-
Bilous, Nadiia, Bomben, Riccardo, Dal Bo, Michele, Capello, Daniela, Forconi, Francesco, Laurenti, Luca, Bertoni, Francesco, Efremov, Dimitar G., Marasca, Roberto, Del Poeta, Giovanni, Martina, Zoya, Kryachouk, Iryna, Dyagil, Iryna, Gaidano, Gianluca, Chumak, Anatoliy, Gattei, Valter, and Abramenko, Iryna
- Subjects
LYMPHOCYTIC leukemia ,CELL receptors ,LYMPHOPROLIFERATIVE disorders ,CHRONIC lymphocytic leukemia ,HOMOLOGY (Biology) - Abstract
A fraction of chronic lymphocytic leukemia (CLL) carries highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable ( IGHV) genes and heavy-chain complementarity-determining region-3 (HCDR3), often associated with a restricted selection of IG(K/L)V light chains. We analyzed the features of CLL expressing homologous HCDR3 in a cohort of 264 Ukrainian patients by merging them with a recently published reference series of 1426 cases. This approach allowed us to identify 96/264 (36%) cases as expressing homologous HCDR3, subdivided into 47 subsets. Among these, 27 apparently novel subsets were identified, although most of them were composed of two sequences per subset (‘potential subsets’). CLL cases belonging to several stereotyped subsets showed HCDR3 homologies with various autoreactive clones. Our analysis identified molecular and clinical features of a Ukrainian cohort of patients with CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
20. IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia.
- Author
-
Bomben, Riccardo, Dal Bo, Michele, Capello, Daniela, Forconi, Francesco, Bertoni, Francesco, Maffei, Rossana, Laurenti, Luca, Rossi, Davide, Zucca, Emanuele, Degan, Massimo, Marasca, Roberto, Efremov, Dimitar G., Del Poeta, Giovanni, Gaidano, Gianluca, and Gattei, Valter
- Subjects
LETTERS to the editor ,CHRONIC lymphocytic leukemia - Abstract
A letter to the editor discussing prognostic marker in chronic lymphocytic leukaemia is presented.
- Published
- 2010
- Full Text
- View/download PDF
21. Genome wide DNA-profiling of HIV-related B-cell lymphomas.
- Author
-
Capello, Daniela, Scandurra, Marta, Poretti, Giulia, Rancoita, Paola M. V., Mian, Michael, Gloghini, Annunziata, Deambrogi, Clara, Martini, Maurizio, Rossi, Davide, Greiner, Timothy C., Chan, Wing C., Ponzoni, Maurilio, Moreno, Santiago M., Piris, Miguel A., Canzonieri, Vincenzo, Spina, Michele, Tirelli, Umberto, Inghirami, Giorgio, Rinaldi, Andrea, and Zucca, Emanuele
- Subjects
GENOMES ,HODGKIN'S disease ,BURKITT'S lymphoma ,HIV ,LYMPHOMAS - Abstract
Non-Hodgkin lymphomas (NHL) represent a frequent complication of human immunodeficiency virus (HIV) infection. To elucidate HIV-NHL pathogenesis, we performed a genome-wide DNA profiling based on a single nucleotide polymorphism-based microarray comparative genomic hybridization in 57 HIV-lymphomas and, for comparison, in 105 immunocompetent diffuse large B-cell lymphomas (IC-DLBCL). Genomic complexity varied across HIV-NHL subtypes. HIV-Burkitt lymphoma showed a significantly lower number of lesions than HIV-DLBCL ( P = 0·032), whereas the median number of copy number changes was significantly higher in Epstein–Barr virus negative (EBV-) HIV-DLBCL (42·5, range 8–153) compared to EBV+ cases (22; range 3–41; P = 0·029). Compared to IC-DLBCL, HIV-DLBCL displayed a distinct genomic profile with no gains of 18q and specific genetic lesions. Fragile sites-associated genes, including FHIT (FRA3B), WWOX (FRA16D), DCC (FRA18B) and PARK2 (FRA6E) were frequently inactivated in HIV-NHL by interstitial deletions, and a significantly higher prevalence of FHIT alterations was observed in HIV-DLBCL compared to IC-DLBCL. The same genes involved by fragile site deletions were also frequently affected by aberrant methylation of regulative regions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
22. Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands.
- Author
-
Toso, Andrea, Aluffi, Paolo, Capello, Daniela, Conconi, Annarita, Gaidano, Gianluca, and Pia, Francesco
- Subjects
MUCOSA-associated lymphoid tissue lymphoma ,SALIVARY glands ,B cells ,GENES ,METHYLTRANSFERASES ,DNA ,HISTOLOGY - Abstract
Background. To analyze clinical features and to discuss the modality of investigation and treatment of a series of mucosa-associated lymphoid tissue (MALT) lymphomas. To investigate the prevalence of aberrant promoter methylation, responsible for gene inactivation, in a selected panel of genes potentially involved in the pathogenesis of B-cell malignancies as O6-methylguanine-DNA methyltransferase (MGMT), p73, death-associated protein kinase (DAP-k). Methods. Nine patients with primary MALT lymphoma of the salivary glands were retrospectively reviewed. MGMT, p73, DAP-k apoptotic pathways were tested. Results. Methylation of DAP-k was common (5/8; 63%). Histological examination ensured diagnostic confirmation, whereas fine-needle aspiration cytology was not definitively diagnostic. Conclusion. Histological assessment is the gold standard in the diagnosis of salivary gland lesions. Parotidectomy represents a safe and reliable diagnostic tool leading to a definite diagnosis of MALT lymphomas in all cases and curative without other treatment in early-stage MALT lymphoma. © 2009 Wiley Periodicals, Inc. Head Neck, 2009 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
23. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
- Author
-
Capello, Daniela, Rasi, Silvia, Oreste, Pierluigi, Veronese, Silvio, Cerri, Michaela, Ravelli, Erika, Rossi, Davide, Minola, Ernesto, Colosimo, Anna, Gambacorta, Marcello, Muti, Giuliana, Morra, Enrica, and Gaidano, Gianluca
- Abstract
Post-transplant lymphoproliferative disorders (PTLDs) represent a frequent complication of solid organ transplantation. Although most PTLDs arise from recipient lymphoid cells, a considerable fraction of cases may arise from donor B-cells. In an attempt to clarify the histogenesis and pathogenesis of PTLDs derived from donor B-cells, monoclonal PTLDs occurring in liver transplant recipients were chosen as a model to compare donor (D-PTLDs) versus recipient PTLDs (R-PTLDs). The tumour panel included nine D-PTLDs and six R-PTLDs. D-PTLDs were early-onset, EBV-infected lymphoproliferations classified as polymorphic PTLD (P-PTLD; n = 7) or diffuse large B-cell lymphoma (DLBCL; n = 2) with tumour localization confined to the hepatic hilum. All R-PTLDs were late-onset DLBCLs and showed extrahepatic localization. A BCL-6
− /MUM1+ /CD138+/− phenotype, consistent with a post-germinal centre (GC) stage of pre-terminal B-cell differentiation, was observed in all D-PTLDs and in 2/6 R-PTLDs, whereas a BCL6+ /MUM1− /CD138− profile, reminiscent of GC B-cells, was detected in 4/6 R-PTLDs. The presence of somatic IGHV hypermutation was observed in 6/9 D-PTLDs and in 4/6 R-PTLDs, suggesting derivation from antigen-experienced B-cells. IGHV4-39 was the IGHV gene most frequently encountered, being rearranged in 3/9 D-PTLDs. Among IGHV-mutated PTLDs, a mutational profile suggesting antigen stimulation and/or selection was observed in 4/6 D-s and in 2/4 R-PTLDs. The presence of ongoing IGHV mutations was detected in 2/4 D-PTLDs. Aberrant SHM was detected in 10/15 (66.7%) PTLDs, including 6/9 D-PTLDs and 4/6 R-PTLDs. Our findings suggest that (i) D-PTLDs show a clinical presentation distinct from R-PTLDs; (ii) immunophenotypic and genetic features of D-PTLDs are consistent with mature, GC-experienced B-cells; (iii) transformed donor-derived B-cells may experience antigen-driven stimulation and selection, and may acquire genetic lesions during neoplastic expansion in the recipient environment; and (iv) EBV infection and expression of viral oncoproteins may be relevant in the pathogenesis of D-PTLDs. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
24. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
- Author
-
Bomben, Riccardo, Dal Bo, Michele, Capello, Daniela, Forconi, Francesco, Maffei, Rossana, Laurenti, Luca, Rossi, Davide, Del Principe, Maria Ilaria, Zucchetto, Antonella, Bertoni, Francesco, Rossi, Francesca Maria, Bulian, Pietro, Cattarossi, Ilaria, Ilariucci, Fiorella, Sozzi, Elisa, Spina, Valeria, Zucca, Emanuele, Degan, Massimo, Lauria, Francesco, and Del Poeta, Giovanni
- Subjects
CHRONIC lymphocytic leukemia ,B cells ,IMMUNOGLOBULINS ,MOLECULAR genetics ,CHRONIC diseases - Abstract
A fraction of chronic lymphocytic leukaemia (CLL) cases carry highly homologous B-cell receptors (BCR), i.e. characterized by non-random combinations of immunoglobulin heavy-chain variable ( IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), often associated with a restricted selection of IGVK/L light chains. Such ‘stereotyped’ BCR occur more frequently in CLL with unmutated (UM) than mutated (M) IGHV genes. We analysed 1426 IG rearrangements (from 1398 CLL cases) by a clustering driven by HCDR3 similarities. Molecular findings were correlated to time-to-treatment (TTT) and presence of known prognosticators. Sixty-nine clusters (319 IG-rearrangements, 22·4%) with stereotyped BCR were identified. Among 30 confirmed clusters (≥3 IG-rearrangements/cluster), we found 14 novel clusters, of which 11 had M IG rearrangements (M clusters) and predominantly (8/11) used IGHV3 subgroup genes. Recurrent cluster-biased amino acid changes were found throughout IGHV sequences of these ‘M clusters’. Regarding clinical outcome: (i) UM CLL from the IGHV1-2/1-3/1-18/1-46/7-4-1/IGKV1-39 cluster had poorer prognosis than UM/M cases, or UM cases using the same IGHV genes but not in clusters; (ii) M CLL from the IGHV3-21/IGLV3-21 cluster had TTT similar to UM CLL, and shorter than M CLL expressing IGHV3-21 but not in cluster. Altogether, our analysis identified additional molecular and clinical features for CLL expressing stereotyped BCR. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
25. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.
- Author
-
Forconi, Francesco, Rinaldi, Andrea, Kwee, Ivo, Sozzi, Elisa, Raspadori, Donatella, Rancoita, Paola M. V., Scandurra, Marta, Rossi, Davide, Deambrogi, Clara, Capello, Daniela, Zucca, Emanuele, Marconi, Daniela, Bomben, Riccardo, Gattei, Valter, Lauria, Francesco, Gaidano, Gianluca, and Bertoni, Francesco
- Subjects
CHRONIC lymphocytic leukemia ,DNA ,LYMPHOCYTIC leukemia ,TUMORS ,DNA fingerprinting - Abstract
Deletion of 17p ( TP53) identifies a rare subset of chronic lymphocytic leukaemia (17p- CLL) with aggressive behaviour. Genome-wide DNA-profiling was performed to investigate 18 patients with 17p- CLL. All cases had multiple copy-number (CN) changes. Among the several recurrent CN changes identified, 8q24.13-q24.1-gain ( MYC), 8p-loss ( TNFRSF10A/B, also known as TRAIL1/2) and 2p16.1-p14-gain ( REL/BCL11A) appeared frequently represented. 8p-loss and 2p16.1-p14-gain also appeared clinically relevant and predicted significant shorter time from diagnosis to treatment (8p-loss) and overall survival (8p-loss and 2p16.1-p14-gain, P < 0·05). These observations document a highly unstable genome in 17p- CLL and suggest that additional genes outside the TP53 locus may be important for tumour behaviour. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
26. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome.
- Author
-
Rossi, Davide, Cerri, Michaela, Capello, Daniela, Deambrogi, Clara, Rossi, Francesca Maria, Zucchetto, Antonella, De Paoli, Lorenzo, Cresta, Stefania, Rasi, Silvia, Spina, Valeria, Franceschetti, Silvia, Lunghi, Monia, Vendramin, Chiara, Bomben, Riccardo, Ramponi, Antonio, Monga, Guido, Conconi, Annarita, Magnani, Corrado, Gattei, Valter, and Gaidano, Gianluca
- Subjects
CHRONIC lymphocytic leukemia ,B cells ,LYMPHOMAS ,LYMPHOPROLIFERATIVE disorders ,REGRESSION analysis ,HOMOLOGY (Biology) - Abstract
Predictors of chronic lymphocytic leukaemia (CLL) transformation to Richter syndrome (RS) are not established and were investigated in 185 consecutive CLL cases. Actuarial incidence of RS ( n = 17; all diffuse large B-cell lymphomas) at 10 years was 16·2% (95% confidence interval: 8·0–24·4%). At CLL diagnosis, prognosticators of RS by univariate analysis were IGHV homology ≥98% ( P = 0·006), IGHV4-39 usage ( P < 0·001), del13q14 absence ( P = 0·004), expression of CD38 ( P < 0·001) and ZAP70 ( P = 0·004), size ( P < 0·001) and number ( P < 0·001) of lymph nodes, advanced Binet stage ( P = 0·002), and lactate dehydrogenase ( P < 0·001). Multivariate analysis, performed separately for biological and clinical variables, identified CD38 expression [Hazard ratio (HR) = 4·26; P = 0·018], IGHV4-39 usage (HR = 4·29; P = 0·018), and lymph node size ≥3 cm (HR = 9·07; P < 0·001) as independent RS prognosticators. A multivariate model simultaneously analysing biological and clinical variables identified lymph node size ≥3 cm (HR = 6·51; P = 0·001) and del13q14 absence (HR = 4·08; P = 0·031) as independent RS prognosticators. Risk factors of CLL transformation differed from risk factors of CLL progression. These results suggest that CD38 and del13q14 may identify biological subsets of CLL with different RS predisposition. Predominant nodal disease, CD38 expression, IGHV4-39 usage, and absence of del13q14 may help in predicting RS at CLL diagnosis. Close monitoring and a careful biopsy policy are needed in patients carrying transformation risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
27. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia.
- Author
-
Forconi, Francesco, Poretti, Giulia, Kwee, Ivo, Sozzi, Elisa, Rossi, Davide, Rancoita, Paola M. V., Capello, Daniela, Rinaldi, Andrea, Zucca, Emanuele, Raspadori, Donatella, Spina, Valeria, Lauria, Francesco, Gaidano, Gianluca, and Bertoni, Francesco
- Subjects
LEUKEMIA ,HAIRY cell leukemia ,GENOMES ,GENE mapping ,DNA fingerprinting - Abstract
Hairy cell leukaemia (HCL) is a rare B-cell neoplasm for which the molecular mechanisms are largely unknown. High-density genome-wide DNA profiling was performed with Affymetrix 250K arrays to analyse copy number (CN) changes and loss of heterozygosity (LOH) in 16 cases of HCL. Four of 16 cases (25%) demonstrated gross non-recurrent CN deletions. Within the affected regions, we identified genes involved in bone marrow fibrosis ( FGF12) and response to treatment ( TP53) in individual cases. Large regions (>5 Mb) of LOH without any concomitant DNA CN changes were identified in 5/16 (31%) HCL and were indicative of uniparental disomy UD. The germline origin of UD was demonstrated in one case for which a matched normal sample was available. Overall analysis of LOH showed that identical loci were recurrently targeted in chromosomes 1, 2 and 6. As a whole, however, HCL showed a remarkably stable genome. This finding adds to several other features that are unique to HCL among mature B-cell tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
28. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
- Author
-
Capello, Daniela, Deambrogi, Clara, Rossi, Davide, Lischetti, Tiziana, Piranda, Daniela, Cerri, Michaela, Spina, Valeria, Rasi, Silvia, Gaidano, Gianluca, and Lunghi, Monia
- Subjects
MYELOPROLIFERATIVE neoplasms ,CELLULAR immunity ,CYTOKINES ,METHYLATION ,GROWTH factors - Abstract
Ph-negative chronic myeloproliferative disorders (CMPD) are characterized by constitutive Janus kinase-signal transducer and activator of transcription (JAK-STAT) activation. SOCS3, SOCS1 and PTPN6 ( SHP1) are negative regulators of the JAK-STAT pathway. We investigated epigenetic and genetic inactivation of SOCS3, SOCS1 and PTPN6 in 112 CMPD and 20 acute myeloid leukaemia (AML) post-CMPD. SOCS3 methylation occurred at high frequency in both CMPD (46/112; 41·1%) and AML post-CMPD (10/17; 58·8%) and was associated with transcriptional silencing. In contrast, methylation of SOCS1 and PTPN6 was observed in only a fraction of CMPD (15/112, 13·4% for SOCS1; and 8/112, 7·1% for PTPN6) and AML post-CMPD (3/20, 15% for SOCS1; and 1/20, 5% for PTPN6). No somatic mutations of SOCS1 were found in CMPD. SOCS3, SOCS1 and PTPN6 methylation occurred in both JAK2V617F-positive (35·1% for SOCS3; 14·9% for SOCS1; 8·1% for PTPN6) and JAK2V617F-negative (57·1% for SOCS3; 14·3% for SOCS1; and 9·5% for PTPN6) CMPD. These data indicate that methylation of SOCS3 and, to a lesser extent, SOCS1 and PTPN6 is a frequent event in both JAK2V617F-positive and -negative CMPD and may act as an alternative or complementary mechanism to JAK2 mutations, enhancing cytokine signal transduction. The frequent inactivation of SOCS3 is a novel finding in CMPD with potential implications for the molecular pathology of these disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
29. A case of nodular sclerosis Hodgkin’s lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman’s disease: successful response to rituximab and radiotherapy.
- Author
-
Falchi, Lorenzo, Capello, Daniela, Palumbo, Barbara, Rauco, Annamaria, Emili, Rita, Cianciulli, Michele, Pace, Roberta, Capparella, Vincenzo, Liberati, Fabrizio, and Liberati, Anna Marina
- Subjects
EPSTEIN-Barr virus ,IMMUNODEFICIENCY ,LEUCOCYTES ,POLYMERASE chain reaction ,LYMPH nodes ,LYMPHOPROLIFERATIVE disorders - Abstract
We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin’s Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular (PC-HV) form of Castleman’s disease (CD). The CD30- and CD15- positive, Reed-Sternberg/Hodgkin cells, only occasionally expressed the CD20 molecule, but not leukocyte common antigen and latent membrane protein-1. Single-strand polymerase chain reaction failed to detect human herpesvirus 8 or EBV in the involved tissues. At the time of second relapse in July 2005, the clinical picture was characterized by a palpable right hypogastric mass, disclosed at physical exam, in the absence of other enlarged peripheral lymph nodes, subjective symptoms or laboratory profile alterations. Combined hybrid-(18)F-fluorodeoxyglucose positron emission-computerized tomography (18F-FDG PET/CT) showed increased radionuclide uptake in multiple external iliac lymph nodes [standardized uptake value (SUV) of 7.4] and non-palpable left supraclavicular lymph nodes (SUV of 5.8). Relapsing cHL in the context of mixed PC-HV CD was documented in two of three surgically excised abdominal lymph nodes never previously enlarged or involved by any lymphoproliferative disease. Because of the limited disease extension and failure to induce continuous remission with previous conventional chemoradiotherapy, the patient was treated with six rituximab injections. This immunotherapy induced significant reduction in size of supraclavicular lymph nodes as evident at ultrasound (US) scan (<1 vs. 2.5 cm, post- vs. pretherapy), which was confirmed by the 18F-FDG PET/CT in October 2005, despite no modification in SUV of 4.2. 18F-FDG PET/CT also disclosed no radionuclide uptake by abdominal lymph nodes. Thus, a second course of four additional rituximab injections was given and subsequent 18F-FDG PET/CT indicated persistent, but reduced incorporation of radionuclide compared to the pretherapy value (SUV of 2.7) in the supraclavicular area and confirmed a normal metabolic activity in the iliac external lymph nodes. Because of uncertain persistent disease in the supraclavicular nodal site, involved-field radiotherapy (RT) was delivered in that area as consolidation treatment. After completion of rituximab and RT for 16 and 14 months respectively, US and 18F-FDG PET/CT exams were indicative of complete remission. This case is in concordance with previously published data suggesting that rituximab immunotherapy might be a valid option in the treatment of CD and also have a role in the management of relapsing cHL. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
30. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance.
- Author
-
Rossi, Davide, De Paoli, Lorenzo, Franceschetti, Silvia, Capello, Daniela, Vendramin, Chiara, Lunghi, Monia, Conconi, Annarita, Magnani, Corrado, and Gaidano, Gianluca
- Subjects
MONOCLONAL gammopathies ,HYPERGAMMAGLOBULINEMIA ,AUTOIMMUNITY ,THROMBOPENIC purpura ,DIAGNOSIS ,PATIENTS - Abstract
Monoclonal gammopathy of uncertain significance (MGUS) may become symptomatic for autoimmune manifestations. We report on the prevalence and clinical course of immune thrombocytopenic purpura (ITP) observed in a consecutive series of 228 MGUS patients. At MGUS diagnosis, ITP was determined in 6/228 cases, accounting for a prevalence of 2630/100 000 [95% confidence interval (CI): 1210–5620]. One incidental ITP case occurred after 21 months of follow-up. After a follow-up of 681·3 patient-years, the crude incidence of ITP in MGUS was 146·8 per 100 000 patient-year (95% CI: 3·7–817·8). Overall, these observations point to an association between MGUS and ITP. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
31. Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.
- Author
-
Capello, Daniela, Cerri, Michaela, Muti, Giuliana, Lucioni, Marco, Oreste, Pierluigi, Gloghini, Annunziata, Berra, Eva, Deambrogi, Clara, Franceschetti, Silvia, Rossi, Davide, Alabiso, Oscar, Morra, Enrica, Rambaldi, Alessandro, Carbone, Antonino, Paulli, Marco, and Gaidano, Gianluca
- Abstract
Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffuse large B-cell lymphoma, n=35; and Burkitt/Burkitt-like lymphoma, n=5). Among PTLD yielding clonal IGV amplimers, a functional IGV heavy chain (IGHV) rearrangement was found in 40/50 (80.0%) cases, whereas a potentially functional IGV light chain rearrangement was identified in 36/46 (78.3%) PTLD. By combining IGHV and IGV light chain rearrangements, 10/50 (20.0%) PTLD carried crippling mutations, precluding expression of a functional B-cell receptor (BCR). Immunohistochemistry showed detectable expression of IG light chains in only 18/43 (41.9%) PTLD. Failure to detect a functional IGV rearrangement associated with lack of IGV expression. Our data suggest that a large fraction of PTLD arise from germinal centre (GC)-experienced B-cells that display impaired BCR. Since a functional BCR is required for normal B-cell survival during GC transit, PTLD development may implicate rescue from apoptosis and expansion of B-cells that have failed the GC reaction. The high frequency of IGV loci inactivation appears to be a peculiar feature of PTLD among immunodeficiency-associated lymphoproliferations. Copyright © 2006 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
32. B-cell Posttransplant Lymphoproliferative Disorders in Heart and/or Lungs Recipients: Clinical and Molecular-Histogenetic Study of 17 Cases from a Single Institution.
- Author
-
Lucioni, Marco, Capello, Daniela, Riboni, Roberta, Ippoliti, Giovanbattista, Campana, Carlo, Bandiera, Laura, Arcaini, Luca, Rossi, Davide, Cerri, Michaela, Dionigi, Paolo, Lazzarino, Mario, Magrini, Umberto, Viganò, Mario, Gaidano, Gianluca, and Paulli, Marco
- Published
- 2006
- Full Text
- View/download PDF
33. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas.
- Author
-
Rinaldi, Andrea, Kwee, Ivo, Poretti, Giulia, Mensah, Afua, Pruneri, Giancarlo, Capello, Daniela, Rossi, Davide, Zucca, Emanuele, Ponzoni, Maurilio, Catapano, Carlo, Tibiletti, Maria Grazia, Paulli, Marco, Gaidano, Gianluca, and Bertoni, Francesco
- Subjects
LYMPHOPROLIFERATIVE disorders ,TRANSPLANTATION of organs, tissues, etc. ,LYMPHOMAS ,B cells ,CHROMOSOMES - Abstract
Post-transplant lymphoproliferative disorders (PTLD) are a major complication of solid organ transplantation, representing a cause of severe morbidity and mortality. Apart from Epstein–Barr virus infection, knowledge of the pathogenesis of monoclonal PTLD is limited. Powerful analysis techniques, such as whole genomic DNA profiling (array comparative genomic hybridisation), can improve our understanding of PTLD pathogenesis. Whole genome profiling using the Affymetrix GeneChip Human Mapping 10 k 2·0 was performed on 20 PTLD cases and 25 cases of diffuse large B-cell lymphoma (DLBCL) from immunocompetent patients as a control group. Recurrent lesions were detected among all the samples. Chromosome 18q, 7q, 3q and 12 were the most common gains in the control group. Chromosomes 5p and 11p were commonly gained in PTLD–DLBCL. The latter had frequent losses of 6q, 17p, 1p and 9p. Chromosome 12p was the most frequent target of deletions among PTLD–DLBCL cases. Loss of heterozygosity (LOH) did not always match DNA loss: chromosome 10 seemed to be targeted by uniparental disomy in PTLD. Small deletions and gains, involving both known ( BCL2 and PAX5) and unknown genes ( ZDHHC14), were identified. These data suggest that PTLD share, at a lower frequency, common genetic aberrations with DLBCL from immunocompetent patients. The demonstration of 9p13 amplification emphasises the importance of PAX5 in PTLD. The combination of DNA copy number and LOH assessment lead to the hypothesis that uniparental disomy may be a potential mechanism in B-cell lymphomagenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
34. Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.
- Author
-
Sirianni, Maria Caterina, Libi, Fabio, Campagna, Massimo, Rossi, Davide, Capello, Daniela, Sciaranghella, Gaia, Carbone, Antonino, Simonelli, Cecilia, Monini, Paolo, Gaidano, Gianluca, and Ensoli, Barbara
- Subjects
EXUDATES & transudates ,HERPESVIRUSES ,LYMPHOMAS ,EPSTEIN-Barr virus ,MAJOR histocompatibility complex ,KILLER cells - Abstract
Primary effusion lymphomas (PELs) are invariably infected by human herpesvirus type 8 (HHV8) and often co-infected by Epstein–Barr virus (EBV). We found that expression of major histocompatibility complex class I (MHC-I) surface molecules was significantly decreased in PEL cells when compared with HHV8 negative lymphomas, irrespective of EBV infection. MHC-I downregulation rendered PEL cells sensitive to recognition and killing by natural killer (NK) cells. Intriguingly, analysis of MHC-I non-restricted cytotoxicity in two PEL patients indicated a reduced NK cell activity when compared with healthy individuals. These data suggest that PEL outgrowth may require an impaired NK cell function. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
35. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis.
- Author
-
Capello, Daniela, Rossi, Davide, and Gaidano, Gianluca
- Abstract
Post-transplant lymphoproliferative disorders (PTLD) represent a serious complication of solid organ and allogeneic bone marrow transplantation. PTLD generally display B-cell lineage derivation, involvement of extranodal sites, aggressive histology and clinical behaviour, and frequent association with EBV infection. The occurrence of IgV mutations in the overwhelming majority of PTLD documents that malignant transformation targets germinal centre (GC) B-cells and their descendants both in EBV-positive and EBV-negative cases. Analysis of phenotypic markers of B-cell histogenesis, namely BCL6, MUM-1 and CD138, allows further distinction of PTLD histogenetic categories. PTLD expressing the BCL6
+ /MUM1+/− /CD138− profile reflect B-cells actively experiencing the GC reaction and comprise diffuse large B-cell lymphoma (DLBCL) centroblastic and Burkitt lymphoma. PTLD expressing the BCL6− /MUM1+ /CD138− phenotype putatively derive from B-cells that have concluded the GC reaction and comprise the majority of polymorphic PTLD and a fraction of DLBCL. A third group of PTLD is reminiscent of post-GC and pre- terminally differentiated B-cells that show the BCL6− /MUM1+ /CD138+ phenotype and are morphologically represented by either polymorphic PTLD or DLBCL immunoblastic. The molecular pathogenesis of PTLD involves infection by oncogenic viruses, namely Epstein-Barr virus, as well as genetic or epigenetic alterations of several cellular genes. At variance with lymphoma arising in immunocompetent hosts, whose genome is relatively stable, a fraction of PTLD are characterized by microsatellite instability as a consequence of defects in the DNA mismatch repair mechanism. Apart from microsatellite instability, molecular alterations of cellular genes recognized in PTLD include alterations of c- MYC, BCL-6, p53, DNA hypermethylation, and aberrant somatic hypermutation of proto-oncogenes. Copyright © 2005 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
36. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders.
- Author
-
Cerri, Michaela, Capello, Daniela, Muti, Giuliana, Rambaldi, Alessandro, Paulli, Marco, Gloghini, Annunziata, Berra, Eva, Deambrogi, Clara, Rossi, Davide, Franceschetti, Silvia, Conconi, Annarita, Morra, Enrica, Pasqualucci, Laura, Carbone, Antonino, and Gaidano, Gianluca
- Subjects
LYMPHOPROLIFERATIVE disorders ,GENETIC mutation ,B cell lymphoma ,BURKITT'S lymphoma ,IMMUNOGLOBULINS ,GENES ,AIDS - Abstract
The article focuses on somatic hypermutation (SHM) in post-transplant lymphoproliferative disorders (PTLD). Monoclonal PTLD include polymorphic PTLD, diffuse large B-cell lymphoma (DLBCL) and Burkitt/Burkitt-like lymphoma. Most PTLD originate from germinal centre experienced B cells that have undergone the physiological SHM process targeting immunoglobulin variable genes. Aberrant SHM is a pathogenetic mechanism implicated in DLBCL of immunocompetent hosts and acquired immuno-deficiency syndrome related lymphomas that target the 5' region, including coding sequences, of multiple proto-oncogenes relevant to lymphomagenesis.
- Published
- 2004
- Full Text
- View/download PDF
37. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
- Author
-
Ferreri, Andrés J. M., Dell'Oro, Stefania, Capello, Daniela, Ponzoni, Maurilio, Iuzzolino, Paolo, Rossi, Davide, Pasini, Felice, Ambrosetti, Achille, Orvieto, Enrico, Ferrarese, Fabio, Arrigoni, Gianluigi, Foppoli, Marco, Reni, Michele, and Gaidano, Gianluca
- Subjects
METHYLATION ,GENES ,METHOTREXATE ,CENTRAL nervous system diseases ,LYMPHOMAS ,RADIOTHERAPY - Abstract
We investigated the prevalence and prognostic role of CpG island methylation of the reduced folate carrier ( RFC) gene promoter region in primary central nervous system lymphoma (PCNSL) in immunocompetent patients. Genomic DNA from 40 PCNSL was used for methylation-specific polymerase chain reaction and bisulphite genomic sequencing of the RFC promoter region. Human immunodeficiency virus-negative systemic diffuse large B-cell lymphomas (DLBCL) were used as controls ( n = 50). The impact on outcome of RFC promoter methylation was assessed in 37 PCNSL patients treated with high-dose methotrexate (HD-MTX)-based chemotherapy ± radiotherapy. RFC promoter methylation occurred in 12 of 40 (30%) PCNSL and in four of 50 (8%) DLBCL ( P = 0·01). Of 37 PCNSL treated with HD-MTX-based chemotherapy, methylation occurred in nine cases (24%, M-PCNSL), while 28 cases (76%, U-PCNSL) were negative. Three M-PCNSL (33%) and 15 U-PCNSL (54%) achieved complete remission (CR) after primary chemotherapy. Logistic regression confirmed the independent association between CR rate and International Extranodal Lymphoma Study Group score ( P = 0·03), RFC promoter methylation ( P = 0·07) and use of cytarabine ( P = 0·08). The 3-year failure-free survival (FFS) and overall survival for M-PCNSL and U-PCNSL was 0% vs. 31 ± 9% ( P = 0·34) and 0% vs. 31 ± 9% ( P = 0·35) respectively. This is the first study to assess the methylation status of the RFC promoter in human tumour samples. RFC methylation is more common in PCNSL compared with systemic DLBCL, and is associated with a lower CR rate to HD-MTX-based chemotherapy. If confirmed in prospective trials on PCNSL treated with HD-MTX alone, these data may suggest the necessity for alternative strategies in M-PCNSL considering the increased risk of MTX resistance by tumour cells. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
38. The mutator pathway is a feature of immunodeficiency-related lymphomas.
- Author
-
Duval, Alex, Raphael, Martine, Brennetot, Caroline, Poirel, Helene, Buhard, Olivier, Aubry, Alban, Martin, Antoine, Krimi, Amor, Leblond, Veronique, Gabarre, Jean, Davi, Frederic, Charlotte, Frederic, Berger, Francoise, Gaidano, Gianluca, Capello, Daniela, Canioni, Danielle, Bordessoule, Dominique, Feuillard, Jean, Gaulard, Philippe, and Delfau, Marie Helene
- Subjects
LYMPHOMAS ,IMMUNODEFICIENCY ,MICROSATELLITE repeats ,GENETIC mutation ,LYMPHOPROLIFERATIVE disorders ,TUMORS - Abstract
The mutator phenotype caused by defects in the mismatch repair system is observed in a subset of solid neoplasms characterized by widespread microsatellite instability-high (MSl-H). It is known to be very rare in non-Hodgkin lymphomas (NHL), whereas mutator NHL is the most frequent tumor subtype in mismatch repair- deficient mice. By screening a series of 603 human NHL with specific markers of the mutator phenotype, we found here 12 MSI-H cases (12/603, 2%). Of interest we demonstrated that this phenotype was specifically associated with immunodeficiency-related lymphomas (ID-RL), because it was observed in both posttransplant lymphoproliferative disorders (9/111, 8.1%) and HIV infection- related lymphomas (3/128, 2.3%) but not in a large series of NHL arising in the general population (0/364) (P < 0.0001). The M5l pathway is known to lead to the production of hundreds of abnormal protein neoantigens that are generated in MSl-H neoplasms by frameshift mutations of a number of genes containing coding microsatellite sequences. As expected, MSI-H ID-RL were found to harbor such genetic alterations in 12 target genes with a putative role in lymphomagenesis. The observation that the MSl-H phenotype was restricted to HIV infection-related lymphomas and posttransplant lymphoproliferative disorders suggests the existence of the highly immunogenic mutator pathway as a novel oncogenic process in lymphomagenesis whose role is favored when host immunosurveillance is reduced. Because MSl-H-positive cases were found to be either Epstein-Barr virus-positive or -negative, the mutator pathway should act synergistically or not with this other oncogenic factor, playing an important role in ID-RL. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
39. research paper Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency.
- Author
-
Forconi, Francesco, Capello, Daniela, Berra, Eva, Rossi, Davide, Gloghini, Annunziata, Cerri, Michaela, Muti, Giuliana, Morra, Enrica, Paulli, Marco, Magrini, Umberto, Lucioni, Marco, Rambaldi, Alessandro, Lauria, Francesco, Carbone, Antonio, Stevenson, Freda K., and Gaidano, Gianluca
- Subjects
GLYCOSYLATION ,B cells ,LYMPHOMAS ,IMMUNODEFICIENCY ,ANTIBODY diversity ,HEMATOLOGY - Abstract
Novel N-glycosylation sites are introduced by somatic mutation into the V genes of the majority of follicular lymphomas. Sites are positively selected and rare in normal memory B cells, indicating a potential role in tumour survival in the germinal centre (GC). The incidence of c. 40% in diffuse large B-cell lymphomas (DLBCL) parallels the known heterogenity of the disease. Immunodeficiency-related non-Hodgkin's lymphomas (NHL) include post-transplant lymphoproliferative disorders (PTLD) and acquired immunodeficiency syndrome-related NHL (AIDS-NHL). Most PTLD derive from B cells that carry mutated V
H genes and that have completed the GC reaction. All AIDS-NHL carry mutated VH genes and variable features of GC or post-GC cells. To determine if N-glycosylation is a feature of immunodeficiency-related lymphomas, we analysed the VH genes of 19 PTLD and 36 AIDS-NHL. Novel sites were rare in PTLD (4/19), similar to memory B cells ( P = 0·15). AIDS-NHL, including DLBCL and Burkitt's lymphomas (BL), showed heterogeneity with 16 of 36 (44%) having novel sites. The findings indicate no selection of N-glycosylation sites in PTLD, consistent with post-GC features. The variable incidence of N-glycosylation sites in AIDS-NHL mirrors that in DLBCL and sporadic BL of immunocompetent hosts, supporting the known heterogeneity of these disorders, and possibly pointing to distinct routes of tumour development. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
40. Short Report Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas.
- Author
-
Rossi, Davide, Gaidano, Gianluca, Gloghini, Annunziata, Deambrogi, Clara, Franceschetti, Silvia, Berra, Eva, Cerri, Michaela, Vendramin, Chiara, Conconi, Annarita, Viglio, Alessandra, Muti, Giuliana, Oreste, Pierluigi, Morra, Enrica, Paulli, Marco, Capello, Daniela, and Carbone, Antonino
- Subjects
HEMATOLOGY ,BLOOD diseases - Abstract
Aberrant promoter hypermethylation is a mechanism of tumour suppressor gene inactivation. We explored aberrant promoter hypermethylation of multiple genes in 88 human immunodeficiency virus (HIV)-non Hodgkin lymphomas (NHL), 25 post-transplant lymphoproliferative disorders (PTLD) and five common variable immunodeficiency (CVI)-related NHL. Twenty-six of 79 (32·9%) HIV-NHL, eight of 14 (57·1%) PTLD and two of five (40·0%) CVI–NHL showed aberrant hypermethylation of O
6 -methylguanine-DNA methyltransferase ( MGMT). Aberrant hypermethylation of death-associated protein-kinase ( DAP-K) occurred in 70 of 84 (83·3%) HIV–NHL, 19 of 25 (72·0%) PTLD and three of five (60·0%) CVI–NHL. These data implicate MGMT and DAP-K hypermethylation in lymphomagenesis of immunodeficient hosts. In particular, promoter hypermethylation of DAP-K represents the most frequent molecular alteration yet identified in immunodeficiency-related lymphomas. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
41. Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture.
- Author
-
Chiaramonte, Raffaella, Calzavara, Elisabetta, Balordi, Francesca, Sabbadini, Marta, Capello, Daniela, Gaidano, Gianluca, Serra, Anna, Comi, Paola, and Sherbet, G. V.
- Published
- 2003
- Full Text
- View/download PDF
42. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab.
- Author
-
Golay, Joseè, Gramigna, Rosanna, Facchinetti, Valeria, Capello, Daniela, Gaidano, Gianluca, and Introna, Martino
- Subjects
AIDS ,LYMPHOMAS ,CELL-mediated cytotoxicity ,RITUXIMAB - Abstract
Summary. Rituximab (Mabthera) and alemtuzumab (Campath
® , Mabcampath® ) are non-conjugated IgG1 therapeutic monoclonal antibodies directed against the CD20 and CD52 surface antigens respectively. They are presently used in the therapy of indolent B-cell non-Hodgkin's lymphoma (B-NHL) and of B-cell chronic lymphocytic leukaemia, and are thought to act mainly through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Here we have analysed the capacity of these two monoclonal antibodies to lyse cell lines of acquired immunodeficiency syndrome (AIDS)-related B-NHL through either complement activation or antibody-dependent cytotoxicity. Rituximab strongly activated both CDC and ADCC against CD20-positive AIDS-NHL cells lines, inducing up to 60–98% and 20% specific lysis respectively. In contrast, alemtuzumab was a poor activator of CDC, even in the AIDS-NHL cell lines expressing high amounts of CD52, leading to a lysis of only 1–30%, whereas it was at least as strong as rituximab in inducing ADCC of the same lines (up to 30% specific lysis). Altogether, these data offer a first in vitro rationale supporting the therapeutic use of rituximab for CD20-positive AIDS-NHL. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
43. Molecular histogenesis of plasmablastic lymphoma of the oral cavity.
- Author
-
Gaidano, Gianluca, Cerri, Michaela, Capello, Daniela, Berra, Eva, Deambrogi, Clara, Rossi, Davide, Larocca, Luigi Maria, Campo, Elias, Gloghini, Annunziata, Tirelli, Umberto, and Carbone, Antonino
- Subjects
B cell lymphoma ,HIV - Abstract
Summary. Plasmablastic lymphoma (PBL) of the oral cavity is an aggressive B-cell lymphoma associated with human immunodeficiency virus infection. Although the lymphoma phenotype is consistent with late B-cell maturation, the molecular histogenesis of PBL is unknown. We investigated PBL of the oral cavity (n = 12) for mutations of immunoglobulin variable heavy chain (IgV
H ) and BCL -6 genes, which are acquired by B cells at the time of germinal centre (GC) transit, and for expression of BCL-6, MUM-1 and CD138, which distinguish GC B cells from post-GC B cells. Somatic IgVH hypermutation occurred in 4/10 PBL whereas 6/10 PBL displayed germline IgVH genes. Among PBL carrying hypermutated IgVH genes, the pattern of IgVH mutations was consistent with antigen stimulation in two cases. Mutations of the BCL -6 gene were restricted to 1/12 patients with PBL of the oral cavity. All cases of PBL of the oral cavity displayed the BCL-6– /MUM-1+ /CD138+ phenotype that is consistent with late stage of B-cell differentiation. Overall, these data indicate that, despite a common phenotype and an apparently similar degree of differentiation, PBL of the oral cavity are characterized by histogenetic heterogeneity. A subset of PBL of the oral cavity carried the molecular clues of GC transit and conceivably originated from a B-cell subset corresponding to post-GC B cells. Conversely, another fraction of these lymphomas were devoid of somatic IgVH mutations and appeared to originate from naive B cells that have undergone preterminal differentiation independent of GC transit. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
44. Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions
- Author
-
Nardini, Elena, Rizzi, Simona, Capello, Daniela, Vitolo, Umberto, Gaidano, Gianluca, Menard, Sylvie, and Balsari, Andrea
- Subjects
CHRONIC lymphocytic leukemia ,IMMUNOGLOBULINS - Abstract
We investigated 38 cases of B-cell chronic lymphocytic leukemia (B-CLL) for the presence of non-productive rearrangements in the Sμ regions and defined for the first time the molecular nature of these rearrangements. Southern blot analysis revealed Sμ region rearrangements in 13 cases (34%) and polymerase chain reactions (PCRs) indicated that these rearrangements consisted of internal deletions of the Sμ region. Long-distance PCRs localized the Sμ deletions in the V
H DJH rearranged allele in most cases. We investigated if Sμ deletions were related to VH somatic mutations that, together with isotype switch recombination, are indicative of the B-cell maturation stage. No significant correlation between the presence of Sμ deletions and VH somatic mutations was found, indicating that the two processes are independent in B-CLL. Moreover no significant correlation between Sμ deletions and prognosis was observed. Having shown that Sμ internal deletions are not chromosome translocations rules out their involvement in the onset of malignancy, while their localization in the VH DJH rearranged alleles suggests a possible role in the stabilization of the isotype of the expressed immunoglobulin. [Copyright &y& Elsevier]- Published
- 2002
- Full Text
- View/download PDF
45. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.
- Author
-
Esteller, Manel, Gaidano, Gianluca, Goodman, Steven N, Zagonel, Vittorina, Capello, Daniela, Botto, Barbara, Rossi, Davide, Gloghini, Annunziata, Vitolo, Umberto, Carbone, Antonino, Baylin, Stephen B, and Herman, James G
- Subjects
ANTINEOPLASTIC agents ,B cell lymphoma ,COMPARATIVE studies ,DNA ,GENES ,IMMUNOHISTOCHEMISTRY ,RESEARCH methodology ,MEDICAL cooperation ,POLYMERASE chain reaction ,PROGNOSIS ,RESEARCH ,SURVIVAL analysis (Biometry) ,TRANSFERASES ,EVALUATION research ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,CYCLOPHOSPHAMIDE ,DNA methylation ,PHARMACODYNAMICS - Abstract
Background: The gene encoding the DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT) is transcriptionally silenced by promoter hypermethylation in several human cancers, including diffuse large B-cell lymphoma (B-DLCL). MGMT promoter hypermethylation is a favorable prognostic marker in patients with brain tumors treated with alkylating agents.Methods: In a retrospective cohort study, we used methylation-specific polymerase chain reaction to analyze the MGMT promoter methylation status in tumor DNA of B-DLCL patients receiving cyclophosphamide as part of multidrug regimens. Molecular data were compared with patient response with the use of Student's t test. Disease-free survival and overall survival were estimated by the Kaplan-Meier method and compared with the use of the log-rank test. Multivariable survival analyses were performed with the Cox proportional hazards model. All statistical tests were two-sided.Results: Thirty (36%) of 84 B-DLCL patients showed MGMT promoter hypermethylation in their lymphomas. The presence of MGMT methylation was associated with a statistically significant increase in overall survival (hazard ratio for time to death for nonmethylation versus methylation = 2.8; 95% confidence interval (CI) = 1.2 to 7.5; P =.01) and progression-free survival (hazard ratio for time to progression for nonmethylation versus methylation = 2.6; 95% CI = 1.3 to 5.8; P =.02). MGMT promoter hypermethylation was both independent of and stronger than established prognostic factors, such as age, disease stage, serum lactic dehydrogenase level, and performance status.Conclusion: MGMT promoter hypermethylation appears to be a useful marker for predicting survival in patients with B-DLCL treated with multidrug regimens including cyclophosphamide. [ABSTRACT FROM AUTHOR]- Published
- 2002
46. Hypermethylation of the DNA Repair Gene O[sup 6]-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma.
- Author
-
Esteller, Manel, Gaidano, Gianluca, Goodman, Steven N., Zagonel, Vittorina, Capello, Daniela, Botto, Barbara, Rossi, Davide, Gloghini, Annunziata, Vitolo, Umberto, Carbone, Antonino, Baylin, Stephen B., and Herman, James G.
- Subjects
METHYLTRANSFERASES ,BRAIN tumors - Abstract
Examines the usability of 0&sup6;-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation on predicting survival of patients with brain tumors. Association between MGMT methylation status and MGMT protein expression; Role of MGMT on predicting survival of patients treated with alkylating agents; Effectivity of MGMT on protecting against the toxicity of acrolein.
- Published
- 2002
- Full Text
- View/download PDF
47. Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis.
- Author
-
Carbone, Antonino, Gloghini, Annunziata, Cozzi, Maria Rita, Capello, Daniela, Steffan, Agostino, Monini, Paolo, De Marco, Luigi, and Gaidano, Gianluca
- Subjects
LYMPHOMAS ,KAPOSI'S sarcoma ,HERPESVIRUS diseases - Abstract
Primary effusion lymphoma (PEL) is a peculiar B-cell lymphoma characterized by infection by human herpesvirus type-8/Kaposi sarcoma-associated herpesvirus (HHV-8/KSHV) and by preferential growth in the serous body cavities. Histogenetic studies have suggested that PEL originates from B cells at a late stage of differentiation. In this study, we have investigated PEL for the expression status of MUM1/IRF4 (multiple myeloma 1/interferon regulatory factor 4) protein, which is involved in physiological B-cell maturation and represents a histogenetic marker of late B-cell differentiation. Using multiple detection assays, all cases of PEL (n = 22) were found to express MUM1/IRF4 molecules. MUM1/IRF4 expression was a selective feature of PEL among lymphomas involving the serous body cavities as secondary lymphomatous effusions generally failed to express the protein. In reactive lymphoid tissues, MUM1/IRF4 expression clustered with advanced stages of B-cell differentiation. Comparison of MUM1/IRF4 expression with that of other histogenetic markers defined two phenotypic variants of PEL, i.e. MUM1/IRF4
+ , CD138/syndecan-1+ , B-cell antigen- (20 out of 22 cases) and MUM1/IRF4+ , CD138/syndecan-1- , B-cell antigen+ (2 out of 22 cases), suggesting a certain degree of heterogeneity in the disease histogenesis. The implications of these data are threefold. First, MUM1/IRF4 expression corroborates the notion that PEL originates from post-germinal centre, preterminally differentiated B-cells. Second, MUM1/IRF4 may help in the differential diagnosis of PEL among other lymphomas involving the serous body cavities. Finally, MUM1/IRF4 may interact with HHV-8/KSHV-encoded interferon regulatory factors (IRFs) and thus contribute to PEL escape from interferon-mediated control of viral infection. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
48. The Role of Cytokines in the Pathogenesis and Management of Aids-Related Lymphomas.
- Author
-
Fassone, Lucia, Gaidano, Gianluca, Ariatti, Cristiano, Vivenza, Daniela, Capello, Daniela, Gloghini, Annunziata, Cilia, Anna Maria, Buonaiuto, Daniela, Rossi, Davide, Pastore, Cristina, Carbone, Antonino, and Saglio, Giuseppe
- Subjects
CYTOKINES ,AIDS complications ,LYMPHOMAS ,B cell differentiation ,EXUDATES & transudates - Abstract
Explains the role of cytokines in the pathogenesis and management of AIDS-related lymphomas. Pleiotropic effects of interleukin-10; Function of interleukin-7 in B cell proliferation and differentiation; Involvement of interleukin-6 in B cell differentiation; AIDS-related primary effusion of lymphoma; AIDS-related diffuse large cell lymphoma.
- Published
- 2000
- Full Text
- View/download PDF
49. Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.
- Author
-
Gaidano, Gianluca, Vivenza, Daniela, Forconi, Francesco, Capello, Daniela, Gloghini, Annunziata, Bhatia, Kishor, Gutierrez, Marina, Gallicchio, Margherita, Avanzi, Gian Carlo, Fassone, Lucia, Ariatti, Cristiano, Buonaiuto, Daniela, Cingolani, Antonella, Saglio, Giuseppe, Tirelli, Umberto, Larocca, Luigi M., Dalla-Favera, Riccardo, and Carbone, Antonino
- Published
- 2000
- Full Text
- View/download PDF
50. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen.
- Author
-
Perissi, Valentina, Menini, Nadia, Cottone, Erika, Capello, Daniela, Sacco, Marco, Montaldo, Fabrizio, and De Bortoli, Michele
- Subjects
TRANSCRIPTION factors ,ESTROGEN - Abstract
Transcription of the ERBB2 oncogene is repressed by oestrogen in human breast cancer cells. We show that a 218 bp fragment of the human ERBB2 gene promoter is responsive to oestrogen in transient transfection in ZR75.1 and SKBR.3 cells when the oestrogen receptor is expressed. Deletion analysis of this fragment shows that a sequence located at the 5′ end, which is known to mediate ERBB2 overexpression in breast cancer, is also responsible for the oestrogen response. This sequence binds AP-2 transcription factors and appears functionally identical to an element of the oestrogen-dependent enhancer described in the first intron of human ERBB2. We observed that oestrogen treatment down-regulates expression of AP-2 proteins but does not affect the DNA binding activity of AP-2. Constitutive expression of AP-2β or AP-2γ, but not AP-2α, abrogates the estrogenic repression. Our results demonstrate that AP-2 transcription factors are implicated in the oestrogenic regulation of ERBB2 gene expression and suggest a complex interplay involving the different AP-2 isoforms and other unidentified factors.Oncogene (2000) 19, 280–288 [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.